D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Incidence and risk factors for human immunodeficiency virus seroconversion in a cohort of Sydney homosexual men.
TL;DR: Univariate analysis found that men who seroconverted were significantly more likely to have had a greater number of recent sexual partners, recent amphetamine abuse and a T‐suppressor‐cell count of greater than 800 cells/μL.
Journal ArticleDOI
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.
Bonaventura Clotet,François Raffi,David A. Cooper,Jean François Delfraissy,Adriano Lazzarin,Graeme Moyle,Jürgen K. Rockstroh,Vincent Soriano,Jonathan M. Schapiro +8 more
TL;DR: Enfuvirtide has been shown to provide clinically relevant improvements in CD4 cell counts and reductions in HIV viraemia across all subgroups of treatment-experienced patients studied, including those taking few or no other active drugs.
Journal ArticleDOI
Mediators of Innate and Adaptive Immune Responses Differentially Affect Immune Restoration Disease Associated with Mycobacterium tuberculosis in HIV Patients Beginning Antiretroviral Therapy
Benjamin G. Oliver,Julian Elliott,Julian Elliott,Julian Elliott,Patricia Price,Michael Phillips,Vonthanak Saphonn,Mean Chhi Vun,John M. Kaldor,David A. Cooper,Martyn A. French +10 more
TL;DR: Perturbations of the innate immune response to M. tuberculosis before and during ART may contribute to the immunopathology of TB-IRIS, whereas elevated IL-18 alone suggests adaptive immune responses predominate in ART-TB.
Journal Article
Culture and properties of cells derived from Kaposi sarcoma.
TL;DR: The establishment of four continuous cell cultures isolated from pleural or peritoneal fluid of patients with Kaposi sarcoma suggest that KS cells could sustain their own growth via an autocrine mechanism and support the existence of a paracrine pathway of EC proliferation in KS.
Journal ArticleDOI
Induction-maintenance antiretroviral therapy: proof of concept.
David B. Hall,Julio G.S. Montaner,Peter Reiss,David A. Cooper,Stefano Vella,Catherine Dohnanyi,Maureen Myers,Joep M. A. Lange,Brian Conway +8 more
TL;DR: The potential for sustained antiviral response was explored for patients who began with ZDV-NVP-ddl and subsequently interrupted ddl in this article, where the authors investigated the concept of aggressive initial combination therapy followed by reduction to a less demanding maintenance regimen with respect to its potential for sustaining viral suppression.